Cimalgex®

Cimicoxib

A NEW reference in NSAIDs

Give with confidence!
Efficacy

Cimalgex® Efficacy proven in Peri-Operative Pain field trial (11)

International: France, Germany, Spain
Controlled, multicentre, randomised and blind field trial
237 dogs
5 to 7 days of treatment

Types of surgeries included in the trial

| Orthopaedic surgery          | Hip/coxofemoral articulation
|-------------------------------|----------------------------------
| 47.4%                        | Patella/cruciate ligaments       |
|                               | Fracture fixation                |
| Soft tissues                 | Castration/genital surgery       |
| 52.6%                        | Tumour removal                   |
|                               | Mastectomy                       |

Cimalgex® Efficacy proven in Osteoarthritis field trial (13)

Practitioner’s assessment of pain in dogs with OA treated with Cimalgex® or firocoxib for 90 days

Owner’s pain assessment for dogs treated with Cimalgex® and firocoxib for 90 days
A NEW reference in NSAIDs

Tolerance

Cimalgex® Renal tolerance

Cimicoxib is a selective COX-2 inhibitor eliminated mainly through faeces. No active cimicoxib is eliminated through the urine.\(^{(12,14)}\)

<table>
<thead>
<tr>
<th>Elimination</th>
<th>Faeces</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimicoxib</td>
<td>15%</td>
<td>0%</td>
</tr>
<tr>
<td>Inactive metabolite</td>
<td>62%</td>
<td>23%</td>
</tr>
</tbody>
</table>

Cimalgex® Stable liver parameters in trials\(^{(11,13,16,17)}\)

No modification of pharmacokinetic parameters in dogs with moderate renal impairment were seen.\(^{(14)}\)

![Pharmacokinetic parameters in dogs (healthy and renally impaired) after 9 days of treatment with Cimalgex® (2mg/kg/day)](Figure 6)

There are no contra-indications or special warnings for use of Cimalgex® (2mg/kg/day) in dogs with mild to moderate renal impairment. It is advisable to monitor potentially complicated cases as advised in the Cimalgex® SPC.

Cimalgex® Gastro-intestinal tolerance\(^{(9,17)}\)

Endoscopy of the stomach and duodenum should that Cimalgex® was well tolerated at doses up to 10mg/kg/day. A dose-effect relationship was indicated for other gastro-intestinal effects; however, in the recommended dose (2mg/kg/day) group no gastro-intestinal differences were noted from the control group.
Convenience

**Cimalgex® Easy to give**

- Cimalgex® can be given with or without food\(^9\)
- Cimalgex® highly accepted flavoured tablets are taken voluntarily by a great majority of dogs\(^{18}\).

**easy to break**

**chewable**

<table>
<thead>
<tr>
<th>Easy dispensing of blister packs for short term cases</th>
<th>Convenient 32 tablet pack for long term cases</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Blister packs" /></td>
<td><img src="image2" alt="32 tablet pack" /></td>
</tr>
</tbody>
</table>

**Cimalgex® administration:**

- 2mg/kg bodyweight (BW), per os, once daily.
- Cimalgex® treats all dogs over 10 weeks of age\(^9\).

<table>
<thead>
<tr>
<th>Tablet Strength</th>
<th>3-4</th>
<th>4.1-7.5</th>
<th>7.6-15</th>
<th>15.1-20</th>
<th>20.1-40</th>
<th>40.1-60</th>
<th>&gt; 60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimalgex® 8mg</td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
<td><img src="image3" alt="8mg" /></td>
</tr>
<tr>
<td>Cimalgex® 30mg</td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
<td><img src="image4" alt="30mg" /></td>
</tr>
<tr>
<td>Cimalgex® 80mg</td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
<td><img src="image5" alt="80mg" /></td>
</tr>
</tbody>
</table>
Give with confidence!

**Efficacy**

Proven efficacy in peri-operative and osteoarthritis pain management
Rapidly available in the blood for potent pain reduction

**Tolerance**

No active cimicoxib is eliminated through the urine
Stable liver parameters in trials
High gastro-intestinal tolerance

**Convenience**

Highly accepted, chewable and splitable tablets
Can be given with or without food
Three tablet strengths to enable easy dosing
**References**

1. International Association for the Study of Pain (IASP); www.iasp-pain.org
9. Cimicox summary of product characteristics and scientific discussion; Vetoquinol SA, Magny-Veronis BP 189, 70024 Lure cedex, FR
11. E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peripertaneous pain in dogs; 2008, study number 3038028F1
13. S. Rouger: Assessment of the efficacy and safety of cimicoxib compared to Reboxic in dogs with osteoarthritis; 2008, study number V3080001F1
14. E. Jeunesses, H. Lefebvre, P.L Tourien: Disposition of cimicoxib in normal and renal impaired dogs; 2009, Vetoquinol study number 3008P5F2_R
15. Zapater J., Casadeus A., de Luna M. and Santauscaga C.: Toxicity in Beagle dogs with repeated administration for 5 weeks and a 14 day recovery period: Oral administration; 2000, Vetoquinol study number V209/001F1
16. Casadeus A., Soris R., Marchachelli C., Zapatero J: 39-week toxicity study in Beagle dogs with repeated oral administration and an 8 week recovery period; 2005, Vetoquinol study number CDD02/8317T
17. Voute H.: 26 week oral tablets safety study in the Beagle dog treated with Cimicox at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number 300878F1
18. E. Berenouez, Evaluacion comparativa de l’acceptance de quatre anti-inflammatoires non steroïdianes chez en chien adulte ; 2010, Vetoquinol study number V3080898F1 / R

**Vetoquinol Signe de Passion**

Cimicoxib under licence from PALAU PHARMA, Spain.

Further information is available from:

Vetoquinol UK Limited,
Vetoquinol House, Great Slade,
Buckingham Industrial Park,
Buckingham, MK18 1PA
Tel: 01280 814500
Fax: 01280 825460
Email: office@vetoquinol.co.uk
website: www.vetoquinol.co.uk

Vetoquinol Ireland Limited,
Vetoquinol House, Great Slade,
Buckingham Industrial Park,
Buckingham, MK18 1PA
Tel: 1800 406117
Fax: 1800 406116
Email: ireland@vetoquinol.co.uk
website: www.vetoquinol.co.uk

www.cimydog.com

Please use medicines responsibly.
For further information please visit www.noah.co.uk/responsible